SK pharmteco is developing technology to reduce the manufacturing time for cell and gene therapy from a month to just two or three days, potentially reducing costs and making it more accessible.
CPHI Worldwide, the largest pharmaceutical trade show, started in Barcelona with major Korean biopharma players in attendance. Over 2,500 companies from 170 countries are exhibiting.
SK pharmteco, SK Inc.'s contract bio-manufacturing subsidiary, will showcase its capabilities in small molecule APIs and cell and gene therapy at the CPhI Worldwide convention in Barcelona.
SK pharmteco completed its second facility for Cell and Gene Therapies (C>) manufacturing in Europe, doubling its viral vector production capacity to 10,000 square meters (2.47 acres).
SK Pharmteco will push back its plan to list on the Nasdaq to as early as 2024, after the markets have had time to recover from the current downturn
SK Biotek, a manufacturing subsidiary of SK Pharmteco, began operation of a newly built factory in Sejong, SK Inc. said Tuesday.
SK Pharmteco, a biopharmaceutical subsidiary of SK Group, will prepare for a pre-IPO with the aim of hitting $2 billion in revenue by 2025.
Around 20 Korean biopharmaceutical companies are set to attend the 40th annual J.P. Morgan HealthCare Conference, which will be held online Jan. 10 to 13 and is often referred to as the bio shopping mall for investors around the world.
SK Pharmteco’s U.S. subsidiary will manufacture ingredients of essential medicines, including those for Covid-19, under a massive funding campaign from the U.S. government worth up to $812 million.
Korea JoongAng Daily Sitemap